--- title: "GeneDx - CW27 | 8-K: FY2026 Q1 Revenue: USD 102.25 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/285114495.md" datetime: "2026-05-04T20:13:17.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285114495.md) - [en](https://longbridge.com/en/news/285114495.md) - [zh-HK](https://longbridge.com/zh-HK/news/285114495.md) generator: "portal-rs" --- # GeneDx - CW27 | 8-K: FY2026 Q1 Revenue: USD 102.25 M Revenue: As of FY2026 Q1, the actual value is USD 102.25 M. EPS: As of FY2026 Q1, the actual value is USD -2.16. EBIT: As of FY2026 Q1, the actual value is USD -56.75 M. ### Financial Metrics for GeneDx Holdings Corp. #### Year Ended December 31, 2025 **GAAP Measure** **Total Revenue**: $427,539 thousand, with diagnostic test revenue at $416,668 thousand and other revenue at $10,871 thousand. **Cost of Services**: $129,366 thousand. **Gross Profit**: $298,173 thousand. **Gross Margin**: 69.7%. **Operating Costs**: Research and development was $72,026 thousand, and selling, general and administrative was $239,224 thousand. **Loss from Operations**: -$13,077 thousand. **Interest Expense, Net**: -$2,539 thousand. **Other Expense, Net**: -$5,521 thousand. **Income Tax Benefit**: $116 thousand. **Net Loss**: -$21,021 thousand. **Adjusted Measure** **Total Revenue**: $427,539 thousand, comprising $416,668 thousand from diagnostic test revenue and $10,871 thousand from other revenue. **Cost of Services**: $123,201 thousand. **Gross Profit**: $304,338 thousand. **Gross Margin**: 71.2%. **Operating Costs**: Research and development was $65,496 thousand, and selling, general and administrative was $192,154 thousand. **Income from Operations**: $46,688 thousand. **Other Income, Net**: $512 thousand. **Net Income**: $47,200 thousand. **Non-GAAP Adjustment for Non-Core Lease Costs**: -$5,391 thousand. #### Three Months Ended March 31, 2025 **GAAP Measure** **Total Revenue**: $87,115 thousand, with diagnostic test revenue at $85,759 thousand and other revenue at $1,356 thousand. **Cost of Services**: $28,639 thousand. **Gross Profit**: $58,476 thousand. **Gross Margin**: 67.1%. **Operating Costs**: Research and development was $12,577 thousand, and selling, general and administrative was $50,450 thousand. **Loss from Operations**: -$4,551 thousand. **Interest Expense, Net**: -$640 thousand. **Other Income, Net**: -$891 thousand. **Income Tax Expense**: -$447 thousand. **Net Loss**: -$6,529 thousand. **Adjusted Measure** **Total Revenue**: $87,115 thousand, with diagnostic test revenue at $85,759 thousand and other revenue at $1,356 thousand. **Cost of Services**: $27,396 thousand. **Gross Profit**: $59,719 thousand. **Gross Margin**: 68.6%. **Operating Costs**: Research and development was $11,758 thousand, and selling, general and administrative was $39,028 thousand. **Income from Operations**: $8,933 thousand. **Other Income, Net**: $239 thousand. **Net Income**: $9,172 thousand. **Non-GAAP Adjustment for Non-Core Lease Costs**: -$1,481 thousand. #### Three Months Ended June 30, 2025 **GAAP Measure** **Total Revenue**: $102,692 thousand, consisting of $100,100 thousand from diagnostic test revenue and $2,592 thousand from other revenue. **Cost of Services**: $31,790 thousand. **Gross Profit**: $70,902 thousand. **Gross Margin**: 69.0%. **Operating Costs**: Research and development was $15,079 thousand, and selling, general and administrative was $46,863 thousand. **Income from Operations**: $8,960 thousand. **Interest Expense, Net**: -$817 thousand. **Other Income, Net**: $2,420 thousand. **Income Tax Benefit**: $246 thousand. **Net Income**: $10,809 thousand. **Adjusted Measure** **Total Revenue**: $102,692 thousand, with $100,100 thousand from diagnostic test revenue and $2,592 thousand from other revenue. **Cost of Services**: $30,208 thousand. **Gross Profit**: $72,484 thousand. **Gross Margin**: 70.6%. **Operating Costs**: Research and development was $13,448 thousand, and selling, general and administrative was $42,936 thousand. **Income from Operations**: $16,100 thousand. **Other Income, Net**: $288 thousand. **Net Income**: $16,388 thousand. **Non-GAAP Adjustment for Non-Core Lease Costs**: -$1,405 thousand. #### Three Months Ended September 30, 2025 **GAAP Measure** **Total Revenue**: $116,743 thousand, including $113,523 thousand from diagnostic test revenue and $3,220 thousand from other revenue. **Cost of Services**: $32,216 thousand. **Gross Profit**: $84,527 thousand. **Gross Margin**: 72.4%. **Operating Costs**: Research and development was $19,829 thousand, and selling, general and administrative was $67,949 thousand. **Loss from Operations**: -$3,251 thousand. **Interest Expense, Net**: -$562 thousand. **Other Expense, Net**: -$3,575 thousand. **Income Tax Expense**: -$247 thousand. **Net Loss**: -$7,635 thousand. **Adjusted Measure** **Total Revenue**: $116,743 thousand, with $113,523 thousand from diagnostic test revenue and $3,220 thousand from other revenue. **Cost of Services**: $30,623 thousand. **Gross Profit**: $86,120 thousand. **Gross Margin**: 73.8%. **Operating Costs**: Research and development was $18,034 thousand, and selling, general and administrative was $51,852 thousand. **Income from Operations**: $16,234 thousand. **Other Expense, Net**: -$176 thousand. **Net Income**: $16,058 thousand. **Non-GAAP Adjustment for Non-Core Lease Costs**: -$1,323 thousand. #### Three Months Ended December 31, 2025 **GAAP Measure** **Total Revenue**: $120,989 thousand, including $117,286 thousand from diagnostic test revenue and $3,703 thousand from other revenue. **Cost of Services**: $36,721 thousand. **Gross Profit**: $84,268 thousand. **Gross Margin**: 69.6%. **Operating Costs**: Research and development was $24,541 thousand, and selling, general and administrative was $73,962 thousand. **Loss from Operations**: -$14,235 thousand. **Interest Expense, Net**: -$520 thousand. **Other (Expense) Income, Net**: -$3,475 thousand. **Income Tax Benefit**: $564 thousand. **Net Loss**: -$17,666 thousand. **Adjusted Measure** **Total Revenue**: $120,989 thousand, with $117,286 thousand from diagnostic test revenue and $3,703 thousand from other revenue. **Cost of Services**: $34,974 thousand. **Gross Profit**: $86,015 thousand. **Gross Margin**: 71.1%. **Operating Costs**: Research and development was $22,256 thousand, and selling, general and administrative was $58,338 thousand. **Income from Operations**: $5,421 thousand. **Other (Expense) Income, Net**: $161 thousand. **Net Income**: $5,582 thousand. **Non-GAAP Adjustment for Non-Core Lease Costs**: -$1,182 thousand. #### Q1 2026 Financial Highlights **Segment Revenue** **Total Revenue**: $102.3 million for Q1 2026, a 17.4% increase from Q1 2025’s $87.115 million. **GeneDx segment revenue**: $101,496 thousand for Q1 2026, compared to $87,115 thousand for Q1 2025. **Other segment revenue**: $758 thousand for Q1 2026. **Exome and genome revenue**: Increased by 27% year-over-year to $90.6 million in Q1 2026, up from $71.4 million in Q1 2025 and $44.0 million in Q1 2024. **Other revenue streams for Q1 2026**: Included hereditary cancer revenue of $0.1 million, other panels revenue of $10.6 million, data information revenue of $0.8 million, and software and interpretation services revenue of $0.2 million. **Operational Metrics** **Exome and Genome Volume**: Grew 34% year-over-year in Q1 2026 to 27,488 tests, compared to 20,562 tests in Q1 2025 and 16,592 tests in Q1 2024. **Exome and Genome Portfolio Mix**: Genomes represented 45% of the combined exome and genome portfolio in Q1 2026. **Average Revenue Per Report (ARR)**: Approximately $3,300 in Q1 2026, with blended ARR lower due to a higher genome mix and lower parental samples mix. **Adjusted Gross Margin**: 69% for Q1 2026, with GeneDx contributing 68.9% and Other segments contributing 68.5%. **Total Adjusted Gross Margin**: 68.6% for Q1 2026, remaining flat year-over-year compared to 68.6% for Q1 2025. **Adjusted Gross Profit**: $70,053 thousand in Q1 2026, compared to $59,719 thousand in Q1 2025. **Gross Margin (GAAP)**: 66.7% for Q1 2026, down from 67.1% for Q1 2025. **Gross Profit (GAAP)**: $68,211 thousand for Q1 2026, up from $58,476 thousand for Q1 2025. **Adjusted Total Operating Expenses**: $78.1 million, representing 76% of revenue. **Total GAAP Operating Expenses**: $94.4 million. **GAAP Loss from Operations**: -$57,471 thousand for Q1 2026, compared to -$4,551 thousand in Q1 2025. **Adjusted Loss from Operations**: -$8,024 thousand for Q1 2026, compared to adjusted income from operations of $8,933 thousand in Q1 2025. **Adjusted Net Loss**: -$8.2 million for Q1 2026, compared to an adjusted net income of $9.172 million for Q1 2025. **Net Loss (GAAP)**: -$63,316 thousand for Q1 2026, compared to a net loss of -$6,529 thousand for Q1 2025. **Cash Flow** **Cash Position**: Cash, cash equivalents, marketable securities, and restricted cash totaled $171.7 million as of March 31, 2026. **Net cash used in operating activities**: -$32,408 thousand for Q1 2026, compared to net cash provided by operating activities of $10,182 thousand in Q1 2025. **Net cash used in investing activities**: -$17,255 thousand for Q1 2026, compared to -$9,408 thousand in Q1 2025. #### 2026 Guidance Update GeneDx Holdings Corp. updated its full-year 2026 revenue guidance to between $475 to $490 million, a decrease from the previous guidance of $540 to $555 million. The company expects at least 30% growth in exome and genome volume, down from the prior 33% to 35% range, and anticipates an adjusted gross margin of approximately 70% with positive adjusted net income for the full year. For the second quarter of 2026, the company projects revenue of $110 to $112 million, approximately 30,000 exome and genome tests, an adjusted gross margin of approximately 70%, and an adjusted net loss of approximately -$5 million. #### Other Key Information Beginning with the quarter ended March 31, 2026, GeneDx Holdings Corp. reclassified “selling and marketing” and “general and administrative” into a single line item, “selling, general and administrative.” Additionally, the methodology for adjusted net income (loss) now includes an adjustment for non-core lease costs related to vacant laboratory facilities and office space. ### Related Stocks - [WGSWW.US](https://longbridge.com/en/quote/WGSWW.US.md) ## Related News & Research - [Alexandria Real Estate Equities declares Q3 2026 dividend of R$ 0.63 per unit](https://longbridge.com/en/news/297928934.md) - [Quanta Services announces dividend of R$ 0.03 per unit for Q3 2026](https://longbridge.com/en/news/297931955.md) - [PulteGroup declares Q3 2026 dividend of R$ 0.9 per unit](https://longbridge.com/en/news/297931957.md) - [Americold Realty Trust declares Q3 2026 dividend of R$ 0.27 per unit](https://longbridge.com/en/news/297823075.md) - [J.M. Smucker announces dividend of R$ 1.94 per unit for Q3 2026](https://longbridge.com/en/news/297931100.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**